SRI International To Advance Clinical Development Of TAS-108, A Late-Stage Breast Can

[News]

SRI International, an independent nonprofit research and development organization, announced that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company...

More... (http://mnt.to/f/3HDn)